(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 September 2011 (15.09.2011)

PCT

(10) International Publication Number
WO 2011/112978 A1

(51) International Patent Classification:
*A61K 39/395* (2006.01)

(21) International Application Number:
PCT/US2011/028172

(22) International Filing Date:
11 March 2011 (11.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 61/313,628 | 12 March 2010 (12.03.2010) | US |
| 61/327,314 | 23 April 2010 (23.04.2010) | US |
| 61/412,644 | 11 November 2010 (11.11.2010) | US |


(71) Applicant *(for all designated States except US)*: **IMMUNOGEN, INC.** [US/US]; 830 Winter Street, Waltham, Massachusetts 02451 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DECKERT, Jutta** [US/US]; 16 Eaton Road, Lexington, Massachusetts 02420 (US). **PARK, Peter** [US/US]; 25 Webster Ave, #301, Somerville, Massachusetts 02143 (US). **TAVARES, Daniel** [US/US]; 27 Sylvester Road, Natick, Massachusetts 01760 (US). **RUI, Lingyun** [CN/US]; 11 Arrowhead Road, Weston, Massachusetts 02493 (US).

(74) Agents: **STEFFE, Eric, K.** et al.; Sterne Kessler Goldstein & Fox, P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published**:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/112978 A1

(54) Title: CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF

(57) Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.